Revenue
2018
2019
2020
2021
2022
2023
2024
2025
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $236.3M | $204.7M | $148.7M | $122.3M | $98.0M | $71.1M | $72.6M | $57.6M | $45.6M | $37.3M | $31.0M |
| Gross profit | $172.7M | $148.6M | $111.3M | $90.7M | $73.4M | $55.0M | $54.6M | $42.7M | $34.5M | $26.4M | $21.6M |
| Research & development | $9.1M | $11.0M | $10.9M | $8.5M | $5.5M | $5.3M | $5.7M | $4.7M | $3.4M | $2.2M | $1.8M |
| Operating expenses | $211.9M | $183.6M | $138.0M | $116.1M | $91.4M | $81.8M | $63.7M | $52.2M | $40.9M | $32.5M | $28.2M |
| Operating income | −$39.2M | −$35.0M | −$26.8M | −$25.4M | −$18.0M | −$26.8M | −$9.1M | −$9.6M | −$6.5M | −$6.1M | −$6.6M |
| EBITDAderived | −$18.1M | −$15.9M | −$9.4M | −$12.3M | −$7.3M | −$18.7M | −$4.4M | −$6.7M | −$4.1M | −$4.2M | −$4.7M |
| Net income | −$39.6M | −$37.8M | −$21.0M | $1.3M | −$16.3M | −$32.9M | −$13.7M | −$12.0M | −$8.9M | −$6.6M | −$7.9M |
| Basic EPSper diluted share | -$1.69 | -$1.64 | -$0.92 | $0.06 | -$0.84 | -$1.82 | -$0.94 | -$0.96 | -$5.86 | -$7.14 | -$7.27 |
| Diluted EPSper diluted share | -$1.69 | -$1.64 | -$0.92 | $0.06 | -$0.84 | -$1.82 | -$0.94 | -$0.96 | -$5.86 | -$7.14 | -$7.27 |
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 16, 2026Form 4 | Hauser Joseph WPres. Trauma & Def. Correction | SellCommon Stock | 8.6K | $17.25 | $148.3K | 194.8K |
| Mar 16, 2026Form 4 | Hite FredCOO and CFO | SellCommon Stock | 13.0K | $17.25 | $224.1K | 277.5K |
| Mar 16, 2026Form 4 | Bailey David RPresident and CEO | SellCommon Stock | 19.5K | $17.25 | $337.0K | 298.0K |
| Mar 16, 2026Form 4 | Odle Gregory APresident of Scoliosis | SellCommon Stock | 8.4K | $17.25 | $145.5K | 187.7K |
| Mar 16, 2026Form 4 | Gerritzen Daniel JGeneral Counsel and Secretary | SellCommon Stock | 8.6K | $17.25 | $148.6K | 149.5K |